Edition:
United Kingdom

Biomarin Sees 2019 Revenue Guidance For Palynziq Of $70 Mln To $100 mln


Monday, 7 Jan 2019 

Jan 7 (Reuters) - Biomarin Pharmaceutical Inc ::BIOMARIN PHARMACEUTICAL INC - PHASE 3 VOSORITIDE DATA IN CHILDREN WITH ACHONDROPLASIA EXPECTED YEAR END 2019.BIOMARIN PHARMACEUTICAL - SEES 2019 REVENUE GUIDANCE FOR PALYNZIQ OF $70 MILLION TO $100 MILLION.BIOMARIN PHARMACEUTICAL -CHMP OPINION FOR PALYNZIQ INJECTION FOR PATIENTS 16 & OLDER WITH PKU ANTICIPATED IN 1Q19 & POTENTIAL APPROVAL IN EU IN 2Q19.